New Fecal Calprotectin Assay
Effective October 16, 2018, Fecal Calprotectin (CALPRO) testing will be performed within Cleveland Clinic’s Microbiology Laboratories.
• Testing will be performed on unpreserved stool specimens using the FDA-approved QUANTA Lite Extended Range ELISA.
• The assay has a reporting range of 27.1 to 3000 μg/g with interpretations of normal (<50 μg/g), borderline (50-120 μg/g), and abnormal (>120 μg/g).
The quantitative detection of calprotectin is an in vitro diagnostic test to aid in the diagnosis of inflammatory bowel disease (IBD) in conjunction with other clinical and laboratory findings. Fecal calprotectin is an indicator of neutrophils in the stool and is not specific for IBD.
Elevations in fecal calprotectin may be caused by proton pump inhibitors, non-steroid-anti-inflammatory-drugs, and intestinal impairments other than IBD (e.g., diverticulitis, celiac disease, infections, cancer).
Comments are closed